open access

Vol 6, No 6 (2010)
Review paper
Published online: 2011-02-24
Get Citation

The management of skin reactions during epidermal growth factor receptor inhibitors in patients with colorectal cancer

Jacek Kryński, Grażyna G. Kamińska, Grażyna Kamińska-Winciorek
Onkol. Prak. Klin 2010;6(6):318-332.

open access

Vol 6, No 6 (2010)
REVIEW ARTICLES
Published online: 2011-02-24

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein expressed by a number of cell types of epithelial origin.
The use of EGFR inhibitors is associated with various adverse effects, including the most common ones: skin reactions (the so-called skin toxicity) developing in over half of the treated patients. Their intensification is often the reason for drug dose reduction or even treatment discontinuance. In view of the existing relationship between the response to treatment with EGFR inhibitors, expressed as progression-free survival or overall survival, and the skin reactions, it is currently recommended to opt for managing and alleviating the skin reactions rather than for reducing the drug dose or discontinuing the therapy with EGFR inhibitors.
There is available only a limited amount of data from clinical trials on this issue, hence the need to collate and systematise the information concerning the practical approach to adverse effects involving skin.
The data contained in this publication may prove useful in everyday clinical practice and facilitate the decision-making as regards the prevention, treatment and alleviation of skin lesions, as well as the therapeutic approach with the use of EGFR inhibitors itself. An effective treatment of skin symptoms ensures appropriate drug dosage and adequate quality of life of the patient.


Onkol. Prak. Klin. 2010; 6, 6: 318–332

Abstract

The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein expressed by a number of cell types of epithelial origin.
The use of EGFR inhibitors is associated with various adverse effects, including the most common ones: skin reactions (the so-called skin toxicity) developing in over half of the treated patients. Their intensification is often the reason for drug dose reduction or even treatment discontinuance. In view of the existing relationship between the response to treatment with EGFR inhibitors, expressed as progression-free survival or overall survival, and the skin reactions, it is currently recommended to opt for managing and alleviating the skin reactions rather than for reducing the drug dose or discontinuing the therapy with EGFR inhibitors.
There is available only a limited amount of data from clinical trials on this issue, hence the need to collate and systematise the information concerning the practical approach to adverse effects involving skin.
The data contained in this publication may prove useful in everyday clinical practice and facilitate the decision-making as regards the prevention, treatment and alleviation of skin lesions, as well as the therapeutic approach with the use of EGFR inhibitors itself. An effective treatment of skin symptoms ensures appropriate drug dosage and adequate quality of life of the patient.


Onkol. Prak. Klin. 2010; 6, 6: 318–332

Get Citation

Keywords

metastatic colorectal cancer; skin toxicity; EGFR inhibitors; panitumumab

About this article
Title

The management of skin reactions during epidermal growth factor receptor inhibitors in patients with colorectal cancer

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 6 (2010)

Article type

Review paper

Pages

318-332

Published online

2011-02-24

Bibliographic record

Onkol. Prak. Klin 2010;6(6):318-332.

Keywords

metastatic colorectal cancer
skin toxicity
EGFR inhibitors
panitumumab

Authors

Jacek Kryński
Grażyna G. Kamińska
Grażyna Kamińska-Winciorek

References (14)
  1. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990; 265: 7709–7712.
  2. Rowinsky E. The erbB Family: Targets for Therapeutic Development Against Cancer and Therapeutic Strategies Using Monoclonal Antibodies and Tyrosine Kinase Inhibitors. Annual Review of Medicine. 2004; 55(1): 433–457.
  3. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183–232.
  4. Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006; 55(4): 657–670.
  5. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658–1664.
  6. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007; 110(5): 980–988.
  7. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008; 19(1): 92–98.
  8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
  9. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7): 1201–1208.
  10. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6(10): 803–812.
  11. NCI-CTCAE. https://cabig-kc.nci.nih. gov/Vocab/KC/index.php/CTCAE.
  12. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10(5): 345–356.
  13. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010; 18(4): 509–522.
  14. Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(8): 1351–1357.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl